News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
712,177 Results
Type
Article (42179)
Company Profile (294)
Press Release (669704)
Section
Business (210303)
Career Advice (2090)
Deals (36617)
Drug Delivery (105)
Drug Development (82953)
Employer Resources (173)
FDA (16530)
Job Trends (15383)
News (355745)
Policy (33857)
Tag
Academia (2579)
Alliances (51317)
Alzheimer's disease (1332)
Approvals (16511)
Artificial intelligence (214)
Bankruptcy (367)
Best Places to Work (11772)
Biotechnology (188)
Breast cancer (228)
Cancer (1741)
Cardiovascular disease (135)
Career advice (1747)
Cell therapy (358)
Clinical research (66794)
Collaboration (677)
Compensation (375)
COVID-19 (2634)
C-suite (163)
Data (1640)
Diabetes (214)
Diagnostics (6367)
Earnings (87127)
Employer resources (150)
Events (113726)
Executive appointments (577)
FDA (17447)
Funding (611)
Gene therapy (260)
GLP-1 (685)
Government (4479)
Healthcare (18949)
Infectious disease (2746)
Inflammatory bowel disease (124)
Interviews (321)
IPO (16737)
Job creations (4055)
Job search strategy (1491)
Layoffs (461)
Legal (8353)
Lung cancer (257)
Manufacturing (245)
Medical device (13347)
Medtech (13352)
Mergers & acquisitions (20246)
Metabolic disorders (569)
Neuroscience (1751)
NextGen: Class of 2025 (6636)
Non-profit (4524)
Northern California (2101)
Obesity (318)
Opinion (218)
Patents (166)
People (58798)
Phase I (20709)
Phase II (29401)
Phase III (22017)
Pipeline (717)
Postmarket research (2653)
Preclinical (8760)
Radiopharmaceuticals (246)
Rare diseases (337)
Real estate (6248)
Regulatory (22774)
Research institute (2361)
Resumes & cover letters (358)
Southern California (1801)
Startups (3717)
United States (18645)
Vaccines (631)
Weight loss (225)
Date
Today (91)
Last 7 days (601)
Last 30 days (2666)
Last 365 days (35014)
2025 (4502)
2024 (35771)
2023 (40631)
2022 (51798)
2021 (56330)
2020 (54793)
2019 (47398)
2018 (35771)
2017 (33139)
2016 (32663)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (781)
Arizona (218)
Asia (40388)
Australia (6471)
California (4795)
Canada (1723)
China (402)
Colorado (220)
Connecticut (231)
Europe (86062)
Florida (691)
Georgia (165)
Illinois (466)
Indiana (268)
Japan (125)
Maryland (747)
Massachusetts (3659)
Michigan (200)
Minnesota (336)
New Jersey (1362)
New York (1366)
North Carolina (852)
Northern California (2101)
Ohio (173)
Pennsylvania (1102)
South America (1161)
Southern California (1801)
Texas (711)
Utah (143)
Washington State (474)
712,177 Results for "biomarin pharmaceutical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Opinion
Competition for Achondroplasia Treatments Heats Up Slowly
Achondroplasia, which affects around one in 20,000 babies, has just one approved treatment: BioMarin’s Voxzogo. However, new investigational treatments are vying to compete in the area.
January 27, 2025
·
4 min read
·
Jia Jie Chen
Earnings
BioMarin Surpasses Analysts’ Q3 Sales Estimates Despite Voxzogo’s Slight Miss
The biotech beat Wall Street’s third-quarter revenue forecast by 6%, driven by increased uptake of its achondroplasia drug Voxzogo. However, William Blair downgraded BioMarin’s shares to market perform due to a “lack of near-term catalysts” and uncertainty around Voxzogo’s potential revenue growth.
October 30, 2024
·
2 min read
·
Tristan Manalac
Podcast
BioMarin Fails to Reassure Investors, Terns Moves Forward in Obesity, ESMO Excitement
BioMarin’s new business strategy leaves investors with questions; Lykos CEO steps down; Terns releases compelling data on oral weight loss candidate; and more.
September 11, 2024
·
1 min read
·
Heather McKenzie
Layoffs
BioMarin to Lay Off 225 Employees Globally
Last week, BioMarin revealed changes to its C-suite; now, the company has announced its second round of layoffs this year, following the termination of 170 employees in May.
August 29, 2024
·
1 min read
·
Angela Gabriel
Press Releases
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance
February 19, 2025
·
28 min read
Gene therapy
BioMarin Narrows Roctavian Efforts to U.S., Germany, Italy as Sales Stagnate
BioMarin Pharmaceuticals on Monday said it is restricting sales of its hemophilia A gene therapy to three countries in an effort to reduce costs and help the treatment become profitable by 2025.
August 6, 2024
·
2 min read
·
Tristan Manalac
C-suite
BioMarin Brings on Roche, Amgen Alums in Executive Restructuring
As the biotech implements a more focused strategy for its Roctavian hemophilia A gene therapy, BioMarin has recruited two seasoned pharma executives to bolster its C-suite.
August 22, 2024
·
2 min read
·
Tristan Manalac
Business
BioMarin Reports Record Financial Results for the First Quarter 2024
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the quarter ended March 31, 2024.
April 24, 2024
·
24 min read
Business
BioMarin Rolls Out $4B Revenue Expectations, as Analysts Wonder About Pipeline
BioMarin executives sought to calm an anxious investor base Wednesday with a public address and pledge to achieve a nearly 50% bump in annual revenue by 2027. But analysts were left wanting.
September 5, 2024
·
7 min read
·
Annalee Armstrong
Biotech Bay
BioMarin Scheduled to Participate in March Investor Conferences
BioMarin Pharmaceutical Inc. today announced management is scheduled to participate in four upcoming investor conferences in March.
March 1, 2024
·
2 min read
1 of 71,218
Next
